Raiees Andrabi, PhD

Institute Investigator
Department of Immunology and Microbiology


Scripps Research Joint Appointments

Institute Investigator, Department of Immunology and Microbial Science
Faculty, Graduate Program

Research Focus

Raiees Andrabi is an Institute Investigator in the Department of Immunology and Microbiology at The Scripps Research Institute. A major focus in his laboratory is to utilize in vitro directed evolution platform combined with structure-guided design approaches to develop vaccine immunogens against complex pathogens such as HIV, Influenza virus, Arenaviruses and Coronaviruses. The other major area of research in his laboratory is to understand the immunological basis of B cell affinity maturation pathways to complex antigen surfaces, both in vaccination and in infection and to utilize this information for designing more effective vaccines. The overall goal is to design vaccine immunogens and immunization strategies that can induce protective broadly neutralizing antibody responses against complex pathogens through vaccination in humans.

Raiees Andrabi earned his PhD degree from the All India Institute of Medical Sciences in Biochemistry and performed his postdoctoral work in Dennis Burton’s laboratory at The Scripps Research Institute.


Ph.D., Biochemistry, All India Institute of Medical Sciences (AIIMS), Delhi, India
M.Sc., Biochemistry, Hamdard University, Delhi, India
B.Sc., Biology, University of Kashmir, Srinagar, India

Selected References



He W-t, Yuan M, Callaghan S, Musharrafieh R, Song G, Silva M, Beutler N, Lee W-H, Yong P, Torres JL, Melo M, Zhou P, Zhao F, Zhu X, Peng L, Huang D, Anzanello F, Ricketts J, Parren M, Garcia E, Ferguson M, Rinaldi W, Rawlings SA, Nemazee D, Smith DM, Briney B, Safonova Y, Rogers TF, Dan JM, Zhang Z, Weiskopf D, Sette A, Crotty S, Irvine DJ, Ward AB, Wilson IA#, Burton DR#Andrabi R#. Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques. Science Translational Medicine. 2022;14(657):eabl9605. doi: doi:10.1126/scitranslmed.abl9605. (#Corresponding author) (Featured article)

He W-t, Musharrafieh R, Song G, Dueker K, Tse LV, Martinez DR, Schäfer A, Callaghan S, Yong P, Beutler N, Torres JL, Volk RM, Zhou P, Yuan M, Liu H, Anzanello F, Capozzola T, Parren M, Garcia E, Rawlings SA, Smith DM, Wilson IA, Safonova Y, Ward AB, Rogers TF, Baric RS#, Gralinski LE#, Burton DR#Andrabi R#. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. Nature Immunology. 2022;23(6):960-70. doi: 10.1038/s41590-022-01222-1. (#Corresponding author). (Cover and featured article).

Zhou P, Yuan M, Song G, Beutler N, Shaabani N, Huang D, He W-t, Zhu X, Callaghan S, Yong P, Anzanello F, Peng L, Ricketts J, Parren M, Garcia E, Rawlings SA, Smith DM, Nemazee D, Teijaro JR, Rogers TF#, Wilson IA#, Burton DR#Andrabi R#. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Science Translational Medicine. 2022;0(0):eabi9215. doi: doi:10.1126/scitranslmed.abi9215. (#Corresponding author). (Featured article)

Zhou P, Song G, He WT, Beutler N, Tse LV, Martinez DR, Schäfer A, Anzanello F, Yong P, Peng L, Dueker K, Musharrafieh R, Callaghan S, Capozzola T, Yuan M, Liu H, Limbo O, Parren M, Garcia E, Rawlings SA, Smith DM, Nemazee D, Jardine JG, Wilson IA, Safonova Y, Rogers TF, Baric RS#, Gralinski LE#, Burton DR#Andrabi R#. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease. (Immunity, revisionbioRxiv. 2022. Epub 20220307. doi: 10.1101/2022.03.04.479488. PubMed PMID: 35291291; PMCID: PMC8923106. (#Corresponding author)

Zhao F, Berndsen ZT, Pedreño-Lopez N, Burns A, Allen JD, Barman S, Lee W-H, Chakraborty S, Gnanakaran S, Sewall LM, Ozorowski G, Limbo O, Song G, Yong P, Callaghan S, Coppola J, Weisgrau KL, Lifson JD, Nedellec R, Voigt TB, Laurino F, Louw J, Rosen BC, Ricciardi M, Crispin M, Desrosiers RC, Rakasz EG, Watkins DI, Andrabi R#, Ward AB#, Burton DR#, Sok D#. Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus. Nature Communications. 2022;13(1). doi: 10.1038/s41467-022-32783-2. (#Corresponding author)

Yuan M, Zhu X, He WT, Zhou P, Kaku CI, Capozzola T, Zhu CY, Yu X, Liu H, Yu W, Hua Y, Tien H, Peng L, Song G, Cottrell CA, Schief WR, Nemazee D, Walker LM, Andrabi R, Burton DR, Wilson IA. A broad and potent neutralization epitope in SARS-related coronaviruses. Proceedings of the National Academy of Sciences of the United States of America. 2022;119(29):e2205784119. Epub 20220629. doi: 10.1073/pnas.2205784119. PubMed PMID: 35767670; PMCID: PMC9304036.

Liu H, Kaku CI, Song G, Yuan M, Andrabi R, Burton DR, Walker LM, Wilson IA. Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron. Commun Biol. 2022;5(1):766. Epub 20220729. doi: 10.1038/s42003-022-03700-6. PubMed PMID: 35906394; PMCID: PMC9336126.

Hurlburt NK, Homad LJ, Sinha I, Jennewein MF, MacCamy AJ, Wan YH, Boonyaratanakornkit J, Sholukh AM, Jackson AM, Zhou P, Burton DR, Andrabi R, Ozorowski G, Ward AB, Stamatatos L, Pancera M, McGuire AT. Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit. Commun Biol. 2022;5(1):342. Epub 20220411. doi: 10.1038/s42003-022-03262-7. PubMed PMID: 35411021; PMCID: PMC9001700.

Zhao F, Keating C, Ozorowski G, Shaabani N, Francino-Urdaniz IM, Barman S, Limbo O, Burns A, Zhou P, Ricciardi MJ, Woehl J, Tran Q, Turner HL, Peng L, Huang D, Nemazee D, Andrabi R, Sok D, Teijaro JR, Whitehead TA, Ward AB, Burton DR, Jardine JG. Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways. iScience. doi: 10.1016/j.isci.2022.104914. PubMed PMID: 104914.

Ouyang WO, Tan TJC, Lei R, Song G, Kieffer C, Andrabi R, Matreyek KA, Wu NC. Probing the biophysical constraints of SARS-CoV-2 spike N-terminal domain using deep mutational scanning. (Science Advances, in pressbioRxiv. 2022:2022.06.20.496903. doi: 10.1101/2022.06.20.496903.

Allen JD, Ivory D, Song SG, He W-t, Capozzola T, Yong P, Burton DR, Andrabi R, Crispin M. The diversity of the glycan shield of sarbecoviruses 1 closely related to SARS-CoV-2. bioRxiv. 2022. doi: 10.1101/2022.08.24.505118.

Kaku CI, Starr TN, Zhou P, Dugan HL, Khalifé P, Song G, Champney ER, Mielcarz DW, Geoghegan JC, Burton DR, Andrabi R, Bloom JD, Walker LM. Evolution of antibody immunity following Omicron BA.1 breakthrough infection. bioRxiv. 2022:2022.09.21.508922. doi: 10.1101/2022.09.21.508922.

Tan TJC, Mou Z, Lei R, Ouyang WO, Yuan M, Song G, Andrabi R, Wilson IA, Kieffer C, Dai X, Matreyek KA, Wu NC. High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike. bioRxiv. 2022:2022.09.24.509341. doi: 10.1101/2022.09.24.509341.

Dadonaite B, Crawford KH, Radford CE, Farrell AG, Yu TC, Hannon WW, Zhou P, Andrabi R, Burton DR, Liu L, Ho DD, Neher RA, Bloom JD. A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike. bioRxiv. 2022:2022.10.13.512056. doi: 10.1101/2022.10.13.512056.

Bibollet-Ruche F, Russell RM, Ding W, Liu W, Li Y, Wagh K, Wrapp D, Habib R, Skelly AN, Roark RS, Sherrill-Mix S, Wang S, Rando J, Lindemuth E, Cruickshank K, Park Y, Baum R, Connell A, Li H, Giorgi EE, Song GS, Ding S, Finzi A, Newman A, Hernandez GE, Machiele E, Cain DW, Mansouri K, Lewis MG, Montefiori DC, Wiehe KJ, Alam SM, Teng I-T, Kwong PD, Andrabi R, Verkoczy L, Burton DR, Korber BT, Saunders KO, Haynes BF, Edwards RJ, Shaw GM, Hahn BH. A germline-targeting chimpanzee SIV envelope glycoprotein elicits a new class of V2-apex directed cross-neutralizing antibodies. bioRxiv. 2022:2022.10.18.512699. doi: 10.1101/2022.10.18.512699.


Song G, He WT, Callaghan S, Anzanello F, Huang D, Ricketts J, Torres JL, Beutler N, Peng L, Vargas S, Cassell J, Parren M, Yang L, Ignacio C, Smith DM, Voss JE, Nemazee D, Ward AB, Rogers T, Burton DR#Andrabi R#. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Nature Communications.2021;12(1):2938. Epub 2021/05/21. doi: 10.1038/s41467-021-23074-3. PubMed PMID: 34011939; PMCID: PMC8134462. (#Corresponding author)

Turner HL, Andrabi R, Cottrell CA, Richey ST, Song G, Callaghan S, Anzanello F, Moyer TJ, Abraham W, Melo M, Silva M, Scaringi N, Rakasz EG, Sattentau QJ, Irvine DJ, Burton DR, Ward AB. Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization. Sci Adv. 2021;7(31). Epub 2021/07/30. doi: 10.1126/sciadv.abh2791. PubMed PMID: 34321200; PMCID: PMC8318364.

Conti S, Kaczorowski KJ, Song G, Porter K, Andrabi R, Burton DR, Chakraborty AK, Karplus M. Design of immunogens to elicit broadly neutralizing antibodies against HIV targeting the CD4 binding site. Proceedings of the National Academy of Sciences of the United States of America. 2021;118(9). Epub 2021/02/28. doi: 10.1073/pnas.2018338118. PubMed PMID: 33637649; PMCID: PMC7936365.

Allen JD, Chawla H, Samsudin F, Zuzic L, Shivgan AT, Watanabe Y, He WT, Callaghan S, Song G, Yong P, Brouwer PJM, Song Y, Cai Y, Duyvesteyn HME, Malinauskas T, Kint J, Pino P, Wurm MJ, Frank M, Chen B, Stuart DI, Sanders RW, Andrabi R, Burton DR, Li S, Bond PJ, Crispin M. Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation. Biochemistry. 2021;60(27):2153-69. Epub 2021/07/03. doi: 10.1021/acs.biochem.1c00279. PubMed PMID: 34213308; PMCID: PMC8262170.

Huang D, Tran JT, Peng L, Yang L, Suhandynata RT, Hoffman MA, Zhao F, Song G, He WT, Limbo O, Callaghan S, Landais E, Andrabi R, Sok D, Jardine JG, Burton DR, Voss JE, Fitzgerald RL, Nemazee D. A Rapid Assay for SARS-CoV-2 Neutralizing Antibodies That Is Insensitive to Antiretroviral Drugs. Journal of immunology. 2021;207(1):344-51. Epub 20210628. doi: 10.4049/jimmunol.2100155. PubMed PMID: 34183368; PMCID: PMC8711645.


Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, Limbo O, Smith C, Song G, Woehl J, Yang L, Abbott RK, Callaghan S, Garcia E, Hurtado J, Parren M, Peng L, Ramirez S, Ricketts J, Ricciardi MJ, Rawlings SA, Wu NC, Yuan M, Smith DM, Nemazee D, Teijaro JR, Voss JE, Wilson IA, Andrabi R, Briney B, Landais E, Sok D, Jardine JG, Burton DR. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956-63. Epub 2020/06/17. doi: 10.1126/science.abc7520. PubMed PMID: 32540903; PMCID: PMC7299280.

Yang YR, McCoy LE, van Gils MJ, Andrabi R, Turner HL, Yuan M, Cottrell CA, Ozorowski G, Voss J, Pauthner M, Polveroni TM, Messmer T, Wilson IA, Sanders RW, Burton DR, Ward AB. Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in Rabbits. Journal of virology. 2020;94(7). Epub 20200317. doi: 10.1128/jvi.01861-19. PubMed PMID: 31941772; PMCID: PMC7081899.

Nogal B, McCoy LE, van Gils MJ, Cottrell CA, Voss JE, Andrabi R, Pauthner M, Liang CH, Messmer T, Nedellec R, Shin M, Turner HL, Ozorowski G, Sanders RW, Burton DR, Ward AB. HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite. Sci Adv. 2020;6(23):eaba0512. Epub 20200605. doi: 10.1126/sciadv.aba0512. PubMed PMID: 32548265; PMCID: PMC7274786.

Pedreño-Lopez N, Ricciardi MJ, Rosen BC, Song G, Andrabi R, Burton DR, Rakasz EG, Watkins DI. An Automated Fluorescence-Based Method to Isolate Bone Marrow-Derived Plasma Cells from Rhesus Macaques Using SIVmac239 SOSIP.664. Mol Ther Methods Clin Dev. 2020;18:781-90. Epub 20200805. doi: 10.1016/j.omtm.2020.08.004. PubMed PMID: 32953929; PMCID: PMC7476808.

Pedreño-Lopez N, Dang CM, Rosen BC, Ricciardi MJ, Bailey VK, Gutman MJ, Gonzalez-Nieto L, Pauthner MG, Le K, Song G, Andrabi R, Weisgrau KL, Pomplun N, Martinez-Navio JM, Fuchs SP, Wrammert J, Rakasz EG, Lifson JD, Martins MA, Burton DR, Watkins DI, Magnani DM. Induction of Transient Virus Replication Facilitates Antigen-Independent Isolation of SIV-Specific Monoclonal Antibodies. Mol Ther Methods Clin Dev. 2020;16:225-37. Epub 20200213. doi: 10.1016/j.omtm.2020.01.010. PubMed PMID: 32083148; PMCID: PMC7021589.


Andrabi R*, Pallesen J*, Allen JD, Song G, Zhang J, de Val N, Gegg G, Porter K, Su CY, Pauthner M, Newman A, Bouton-Verville H, Garces F, Wilson IA, Crispin M, Hahn BH, Haynes BF, Verkoczy L, Ward AB, Burton DR. The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template. Cell reports. 2019;27(8):2426-41.e6. doi: 10.1016/j.celrep.2019.04.082. PubMed PMID: 31116986; PMCID: PMC6533203. (*first author). (Featured article)

Voss JE*, Gonzalez-Martin A*, Andrabi R*, Fuller RP, Murrell B, McCoy LE, Porter K, Huang D, Li W, Sok D, Le K, Briney B, Chateau M, Rogers G, Hangartner L, Feeney AJ, Nemazee D, Cannon P, Burton D. Reprogramming the antigen specificity of B cells using genome-editing technologies. Elife. 2019;8. Epub 2019/01/17. doi: 10.7554/eLife.42995. PubMed PMID: 30648968. (*first author)

von Bredow B, Andrabi R, Grunst M, Grandea AG, 3rd, Le K, Song G, Berndsen ZT, Porter K, Pallesen J, Ward AB, Burton DR, Evans DT. Differences in the Binding Affinity of an HIV-1 V2 Apex-Specific Antibody for the SIVsmm/mac Envelope Glycoprotein Uncouple Antibody-Dependent Cellular Cytotoxicity from Neutralization. mBio. 2019;10(4). Epub 2019/07/04. doi: 10.1128/mBio.01255-19. PubMed PMID: 31266872; PMCID: PMC6606807.


Andrabi R, Voss JE, Liang CH, Briney B, McCoy LE, Wu CY, Wong CH, Poignard P, Burton DR. Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design. Immunity. 2015;43(5):959-73. doi: 10.1016/j.immuni.2015.10.014. PubMed PMID: 26588781; PMCID: PMC4654981. (Cover and featured article)

Andrabi R*, Su CY*, Liang CH, Shivatare SS, Briney B, Voss JE, Nawazi SK, Wu CY, Wong CH, Burton DR. Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development. Immunity. 2017. doi: 10.1016/j.immuni.2017.08.006. PubMed PMID: 28916265. (*first author) (Featured article)

Lee JH*, Andrabi R*, Su CY, Yasmeen A, Julien JP, Kong L, Wu NC, McBride R, Sok D, Pauthner M, Cottrell CA, Nieusma T, Blattner C, Paulson JC, Klasse PJ, Wilson IA, Burton DR, Ward AB. A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic beta-Hairpin Structure. Immunity. 2017;46(4):690-702. doi: 10.1016/j.immuni.2017.03.017. PubMed PMID: 28423342; PMCID: PMC5400778. (*first author)

Voss JE*, Andrabi R*, McCoy LE*, de Val N, Fuller RP, Messmer T, Su CY, Sok D, Khan SN, Garces F, Pritchard LK, Wyatt RT, Ward AB, Crispin M, Wilson IA, Burton DR. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. Cell reports. 2017;21(1):222-35. doi: 10.1016/j.celrep.2017.09.024. PubMed PMID: 28978475. (*first author)

Andrabi R#, Bhiman JN, Burton DR#. Strategies for a multi-stage neutralizing antibody-based HIV vaccine. Curr Opin Immunol. 2018;53:143-51. doi: 10.1016/j.coi.2018.04.025. PubMed PMID: 29775847. (#Corresponding author)

Cao L, Pauthner M, Andrabi R, Rantalainen K, Berndsen Z, Diedrich JK, Menis S, Sok D, Bastidas R, Park SR, Delahunty CM, He L, Guenaga J, Wyatt RT, Schief WR, Ward AB, Yates JR, 3rd, Burton DR, Paulson JC. Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer. Nature communications. 2018;9(1):3693. Epub 2018/09/14. doi: 10.1038/s41467-018-06121-4. PubMed PMID: 30209313; PMCID: PMC6135743.

Cao L, Diedrich JK, Kulp DW, Pauthner M, He L, Park SR, Sok D, Su CY, Delahunty CM, Menis S, Andrabi R, Guenaga J, Georgeson E, Kubitz M, Adachi Y, Burton DR, Schief WR, Yates Iii JR, Paulson JC. Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. Nature communications. 2017;8:14954. doi: 10.1038/ncomms14954. PubMed PMID: 28348411; PMCID: PMC5379070.

Voss JE, Macauley MS, Rogers KA, Villinger F, Duan L, Shang L, Fink EA, Andrabi R, Colantonio AD, Robinson JE, Johnson RP, Burton DR, Haase AT. Reproducing SIVDeltanef vaccine correlates of protection: trimeric gp41 antibody concentrated at mucosal front lines. Aids. 2016. doi: 10.1097/QAD.0000000000001199. PubMed PMID: 27428745.

Khan L, Makhdoomi MA, Kumar S, Nair A, Andrabi R, Clark BE, Auyeung K, Bhattacharya J, Vajpayee M, Wig N, Pantophlet R, Luthra K. Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual. PloS one. 2015;10(5):e0125575. doi: 10.1371/journal.pone.0125575. PubMed PMID: 25962059; PMCID: PMC4427266.

Singh A, Palanichamy JK, Ramalingam P, Kassab MA, Bhagat M, Andrabi R, Luthra K, Sinha S, Chattopadhyay P. Long-term suppression of HIV-1C virus production in human peripheral blood mononuclear cells by LTR heterochromatization with a short double-stranded RNA. J Antimicrob Chemother. 2014;69(2):404-15. Epub 2013/09/12. doi: 10.1093/jac/dkt348. PubMed PMID: 24022068.

Andrabi R, Makhdoomi MA, Kumar R, Bala M, Parray H, Gupta A, Kotnala A, Thirumurthy V, Luthra K. Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy. J Clin Immunol. 2014;34(4):504-13. Epub 2014/04/01. doi: 10.1007/s10875-014-0010-y. PubMed PMID: 24682667.

Almagro JC, Gilliland GL, Breden F, Scott JK, Sok D, Pauthner M, Reichert JM, Helguera G, Andrabi R, Mabry R, Blery M, Voss JE, Lauren J, Abuqayyas L, Barghorn S, Ben-Jacob E, Crowe JE, Jr., Huston JS, Johnston SA, Krauland E, Lund-Johansen F, Marasco WA, Parren PW, Xu KY. Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA. MAbs. 2014;6(3):577-618. Epub 2014/03/05. doi: 10.4161/mabs.28421. PubMed PMID: 24589717; PMCID: PMC4011904.

Andrabi R, Williams C, Wang XH, Li L, Choudhary AK, Wig N, Biswas A, Luthra K, Nadas A, Seaman MS, Nyambi P, Zolla-Pazner S, Gorny MK. Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals. Virology. 2013;439(2):81-8. Epub 2013/03/08. doi: 10.1016/j.virol.2012.12.010. PubMed PMID: 23466102; PMCID: PMC3756680.

Prakash SS, Andrabi R, Kumar R, Lodha R, Kabra SK, Vajpayee M, Luthra K. Antibodies that cross-neutralize the tier-2 pseudoviruses are produced in antiretroviral-naive HIV-1-infected children from northern India. Arch Virol. 2012;157(9):1797-801. Epub 2012/06/08. doi: 10.1007/s00705-012-1357-0. PubMed PMID: 22674340.

Kumar R, Andrabi R, Tiwari A, Prakash SS, Wig N, Dutta D, Sankhyan A, Khan L, Sinha S, Luthra K. A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C. BMC Biotechnol. 2012;12:87. Epub 2012/11/17. doi: 10.1186/1472-6750-12-87. PubMed PMID: 23153214; PMCID: PMC3536577.

Choudhary AK, Andrabi R, Prakash SS, Kumar R, Choudhury SD, Wig N, Biswas A, Hazarika A, Luthra K. Neutralization potential of the plasma of HIV-1 infected Indian patients in the context of anti-V3 antibody content and antiretroviral therapy. [corrected]. J Microbiol. 2012;50(1):149-54. Epub 2012/03/01. doi: 10.1007/s12275-012-1246-y. PubMed PMID: 22367950.

Andrabi R, Kumar R, Bala M, Nair A, Ss P, Kushwaha V, Luthra K. Envelope diversity, characteristics of V3 region and predicted co-receptor usage of human immunodeficiency viruses infecting north Indians. J Microbiol. 2012;50(5):869-73. Epub 2012/11/06. doi: 10.1007/s12275-012-2136-z. PubMed PMID: 23124759.

Andrabi R, Kumar R, Bala M, Nair A, Biswas A, Wig N, Kumar P, Pal R, Sinha S, Luthra K. Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors. Virol J. 2012;9:196. Epub 2012/09/14. doi: 10.1186/1743-422X-9-196. PubMed PMID: 22971578; PMCID: PMC3493341.

Andrabi R, Bala M, Kumar R, Wig N, Hazarika A, Luthra K. Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India. PloS one. 2012;7(8):e43704. Epub 2012/09/07. doi: 10.1371/journal.pone.0043704. PubMed PMID: 22952740; PMCID: PMC3432049.

Prakash SS, Andrabi R, Kumar R, Kabra SK, Lodha R, Vajpayee M, Luthra K. Binding antibody responses to the immunogenic regions of viral envelope in HIV-1-infected Indian children. Viral Immunol. 2011;24(6):463-9. Epub 2011/12/14. doi: 10.1089/vim.2011.0039. PubMed PMID: 22149971; PMCID: PMC3234704.

Andrabi R, Choudhary AK, Bala M, Kalra R, Prakash SS, Pandey RM, Luthra K. Relative reactivity of HIV-1 polyclonal plasma antibodies directed to V3 and MPER regions suggests immunodominance of V3 over MPER and dependence of high anti-V3 antibody titers on virus persistence. Arch Virol. 2011;156(10):1787-94. Epub 2011/07/08. doi: 10.1007/s00705-011-1053-5. PubMed PMID: 21735212.

Dutta Choudhury S, Chaudhury AK, Kalra R, Andrabi R, Wig N, Biswas A, Bala M, Luthra K. Antiretroviral drug resistance mutations in the reverse transcriptase gene of HIV-1 isolates from Northern Indian patients: a follow-up study. Arch Virol. 2010;155(4):563-9. Epub 2010/02/25. doi: 10.1007/s00705-010-0605-4. PubMed PMID: 20180140.


Complete List of my Published Work: https://pubmed.ncbi.nlm.nih.gov/?term=andrabi+r&sort=date


Scripps Research scientists discover antibodies that induce broad immunity against SARS viruses, including emerging variants

COVID-19 patient antibodies point researchers toward broad coronavirus vaccines

Scripps Research discovery could enable broad coronavirus vaccine

Versatile coronavirus antibody may be starting point for broader-acting vaccines

Monkey-infecting virus may provide part of future HIV vaccine

Scripps Research Study Reveals New Clues to How a Successful HIV Vaccine Could Work

TSRI Scientists Find Surprising Trait in Anti-HIV Antibodies